<h3>Purpose/Objective(s)</h3> To evaluate the efficacy, safety and overall survival of locally advanced carcinoma esophagus patients treated with PETCT based dose escalated SIB-RT <h3>Materials/Methods</h3> 38 patients of histopathologically confirmed locoregionally advanced squamous cell carcinoma of esophagus were treated with radical dose escalated SIB-IMRT along with concurrent chemotherapy. 60.2 Gy in 28 fractions at 2.15Gy/fraction was given to PET uptake area alone of primary and node. CTV received 50.4Gy. Concurrent chemotherapy of either platinum or platinum + Taxane was given. Patients who did not undergo surgery were boosted with ILBT 10Gy in 2 fractions. Toxicity profiles recorded. Responses assessed using PETCT and endoscopy. Overall survival assessed. <h3>Results</h3> Among 38 patients of cervical, midthoracic and lower thoracic carcinoma esophagus treated with the above treatment schedule, 50% (19 patients) achieved complete response radiologically and endoscopically at 6 months, 13 patients achieved partial response, 2 patients had Stable disease and 5 patients developed distant metastasis. Median overall survival was 50 months. 78.9% of patients had grade II esophagitis, 13.1% had grade III esophagitis. 10.5% (4 patients) had strictures and needed dilatation. <h3>Conclusion</h3> Dose escalated SIB-IMRT is safe and tolerable and gives better response by giving higher dose to tumor alone and simultaneously lower dose to CTV